FDA grants Genentech's Perjeta® (pertuzumab) accelerated approval for use before surgery in people with HER2-positive early stage breast cancer

(Fleishman-Hillard) The US Food and Drug Administration granted accelerated approval of a Perjeta® (pertuzumab) regimen for neoadjuvant treatment (use before surgery) in people with high-risk, HER2-positive early stage breast cancer.

http://www.eurekalert.org/pub_releases/2013-10/f-fgg100113.php

Source: EurekAlert! - Medicine and Health - October 1, 2013 Category: Global & Universal Source Type: news